{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T21:40:26Z","timestamp":1717796426860},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T00:00:00Z","timestamp":1426204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Katharine Bar and Global Solutions"},{"name":"Bangkok Vaccine Evaluation Group"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,6,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Vaccine clinical trials with active surveillance for infection often use the time to infection as the primary endpoint. A common method of analysis for such trials is to compare the times to infection between the vaccine and placebo groups using a Cox regression model. With new technology, we can sometimes additionally record the precise number of virions that cause infection rather than just the indicator that infection occurred. In this article, we develop a unified approach for vaccine trials that couples the time to infection with the number of infecting or founder viruses. We assume that the instantaneous risk of a potentially infectious exposure for individuals in the placebo and vaccine groups follows the same proportional intensity model. Following exposure, the number of founder viruses is assumed to be generated from some distribution on , which is allowed to be different for the two groups. Exposures that result in are unobservable. We denote the placebo and vaccine means of by and so that measures the proportion reduction in the mean number of infecting virions due to vaccination per exposure. We develop different semi-parametric methods of estimating . We allow the distribution of to be Poisson or unspecified, and discuss how to incorporate covariates that impact the time to exposure and\/or . Interestingly , which is a ratio of untruncated means, can be reliably estimated using truncated data (), even if the placebo and vaccine distributions of are completely unspecified. Simulations of vaccine clinical trials show that the method can reliably recover in realistic settings. We apply our methods to an HIV vaccine trial conducted in injecting drug users.<\/jats:p>","DOI":"10.1111\/biom.12277","type":"journal-article","created":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T16:27:57Z","timestamp":1426264077000},"page":"386-396","source":"Crossref","is-referenced-by-count":8,"title":["Incorporating Founder Virus Information in Vaccine Field Trials"],"prefix":"10.1093","volume":"71","author":[{"given":"Dean","family":"Follmann","sequence":"first","affiliation":[{"name":"Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases , 6700B Rockledge Drive MSC 7609, Bethesda, Maryland 20892 , U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiung-Yu","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Bioinformatics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University , 550 N. Broadway, Baltimore, Maryland 21205 , U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,3,13]]},"reference":[{"key":"2024010914321430100_biom12277-bib-0001","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/sim.4780131803","article-title":"Reduction in burden of illness: A new efficacy measure for prevention trials","volume":"13","author":"Chang","year":"1994","journal-title":"Statistics in Medicine"},{"key":"2024010914321430100_biom12277-bib-0002","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/j.1541-0420.2006.00569.x","article-title":"Augmented designs to assess immune response in vaccine trials","volume":"62","author":"Follmann","year":"2006","journal-title":"Biometrics"},{"key":"2024010914321430100_biom12277-bib-0003","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/biostatistics\/kxm028","article-title":"The two-sample problem for failure rates depending on a continuous mark: An application to vaccine efficacy","volume":"9","author":"Gilbert","year":"2008","journal-title":"Biostatistics"},{"key":"2024010914321430100_biom12277-bib-0004","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1002\/sim.3122","article-title":"Evaluating a surrogate endpoint at three levels, with application to vaccine development","volume":"27","author":"Gilbert","year":"2008","journal-title":"Statistics in Medicine"},{"key":"2024010914321430100_biom12277-bib-0005","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/01621459.2013.786649","article-title":"Sensitivity analysis of per-protocol time-to-event treatment efficacy in randomized clinical trials","volume":"108","author":"Gilbert","year":"2013","journal-title":"Journal of the American Statistical Association"},{"key":"2024010914321430100_biom12277-bib-0006","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-68636-3","volume-title":"Design and Analysis of Vaccine Studies.","author":"Halloran","year":"2010"},{"key":"2024010914321430100_biom12277-bib-0007","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1073\/pnas.0802203105","article-title":"Identification and characterisation of transmitted and early founder virus envelopes in primary HIV-1 infection","volume":"105","author":"Keele","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"2024010914321430100_biom12277-bib-0008","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/sim.790","article-title":"Comparisons of two-part models with competitors","volume":"20","author":"Lachenbruch","year":"2001","journal-title":"Statistics in Medicine"},{"key":"2024010914321430100_biom12277-bib-0009","doi-asserted-by":"crossref","first-page":"e1002880","DOI":"10.1371\/journal.ppat.1002880","article-title":"Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing","volume":"8","author":"Li","year":"2012","journal-title":"PLOS Pathogens"},{"key":"2024010914321430100_biom12277-bib-0010","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1541-0420.2005.00516.x","article-title":"A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proof-of-concept HIV vaccine trial","volume":"62","author":"Mehrotra","year":"2006","journal-title":"Biometrics"},{"key":"2024010914321430100_biom12277-bib-0011","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/01621459.2000.10474219","article-title":"On profile likelihood","volume":"95","author":"Murphy","year":"2000","journal-title":"Journal of the American Statistical Association"},{"key":"2024010914321430100_biom12277-bib-0012","article-title":"The use of founder virus information in repeated low dose challenge models","author":"Nason","year":"2014","journal-title":"Working Manuscript."},{"key":"2024010914321430100_biom12277-bib-0013","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1086\/508748","article-title":"Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand","volume":"194","author":"Pitisuttithum","year":"2006","journal-title":"Journal of Infectious Diseases"},{"key":"2024010914321430100_biom12277-bib-0014","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2307\/2530374","article-title":"The analysis of failure times in the presence of competing risks","volume":"34","author":"Prentice","year":"1978","journal-title":"Biometrics"},{"key":"2024010914321430100_biom12277-bib-0015","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.2517-6161.1996.tb02113.x","article-title":"Counting process models for infectious disease data: Distinguishing exposure to infection from susceptibility","volume":"58","author":"Rhodes","year":"1996","journal-title":"Journal of the Royal Statistical Society, Series B"},{"key":"2024010914321430100_biom12277-bib-0016","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nature12893","article-title":"Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV","volume":"505","author":"Roederer","year":"2014","journal-title":"Nature"},{"key":"2024010914321430100_biom12277-bib-0017","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1214\/07-AOS554","article-title":"Proportional hazards models with continuous marks","volume":"37","author":"Sun","year":"2009","journal-title":"The Annals of Statistics"},{"key":"2024010914321430100_biom12277-bib-0018","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1198\/016214507000000130","article-title":"Sensitivity analyses comparing time-to-event outcomes existing only in a subset selected postrandomization","volume":"102","author":"Shepherd","year":"2007","journal-title":"Journal of the American Statistical Association"},{"key":"2024010914321430100_biom12277-bib-0019","author":"Sterrett","year":"2014","journal-title":"Low multiplicity of HIV-1 infection and no vaccine enhance in VAX003 injection drug users. Working Manuscript"},{"key":"2024010914321430100_biom12277-bib-0020","volume-title":"Asymptotic Statistics.","author":"van der Vaart","year":"2000"},{"key":"2024010914321430100_biom12277-bib-0021","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1086\/429411","article-title":"Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda","volume":"191","author":"Wawer","year":"2005","journal-title":"Journal of Infectious Diseases"}],"container-title":["Biometrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbiom.12277","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/biometrics\/article-pdf\/71\/2\/386\/55131540\/biometrics_71_2_386.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/biometrics\/article-pdf\/71\/2\/386\/55131540\/biometrics_71_2_386.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T20:54:58Z","timestamp":1717793698000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/biometrics\/article\/71\/2\/386-396\/7511440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,13]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,3,13]]},"published-print":{"date-parts":[[2015,6,1]]}},"URL":"https:\/\/doi.org\/10.1111\/biom.12277","relation":{},"ISSN":["0006-341X","1541-0420"],"issn-type":[{"value":"0006-341X","type":"print"},{"value":"1541-0420","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,6]]},"published":{"date-parts":[[2015,3,13]]}}}